The D(-) isomer of lactic acid appears to cause a form of metabolic encephalopathy experienced by patients who have had jejunoileal bypass for morbid obesity. However, analysis for o(-)-lactate is not routinely available in clinical or reference laboratories. We describe an enzymic centrifugal-analyzer assay for D(-)-lactate in plasma or serum, with use of D(-)-lactate dehydrogenase. The method involves two-point kinetic calibration and preincubation of specimen and NAD, thus eliminating the need for specimen-blanking or proteinprecipitating pretreatment. This rapid, accurate, and precise assay should be helpful in evaluating patients with "shortbowel syndrome" who display confusion, lethargy, ataxia, or other central nervous-system disturbances that may be ascribable to D(-)-lactic acidosis. has not been considered to be of significant clinical importance in humans until 1979, when a patient was reported (1) who had had most of his jejunum removed because of superior mesenteric artery thrombosis with small bowel gangrene and about two years later had presented with repeated episodes of fluctuatingencephalopathy and metabolic acidosis. D(-)-Lactic acid was eventually discovered to be the cause of the patient's symptoms when his urine was examined for an unusual organic acid, thought possibly to come from colomc bacteria. This acid had a plC5 and gas-liquid chromatographic properties identical to those for iA+)-lactic acid. The usual gas-liquid chromatography involving derivitization with non-chiral compounds will measure L(+)-and n(-)-lactic acid as identical compounds. The enantiomers of lactic may be separated by gas-liquid chromatography by use of a chiral stationary phase or by use of derivitization of the enantiomers into diastereomers with a chiral alcohol, usually l(-)-menthol (2). An easier approach for determination of n(-)-lactic acid is to use a specific n(-)-lactate dehydrogenase (EC 1.1.1.28)  from microorganisms (3-5) .
is to use a specific n(-)-lactate dehydrogenase (EC 1.1.1.28) from microorganisms (3) (4) (5) .
Subsequently, D( -)-lactic acidosis has been shown to be the agent causing a fluctuating encephalopathy characterized by dizziness, ataxia, headache, lethargy, memory lapses, and metabolic acidosis in several patients who have had jejunoileal bypass for morbid obesity (6-9). Results of routine clinical laboratory enzymic determinations of "lactic acid," measuring only L( + )-lactic acid, were normal in these patients. In ruminants, which can get r)(-)-lactic acidosis from over-feedingwith grain (10), and in man, the degree of encephalopathy appears to correlate with the concentration of n(-)-lactate in serum. The n(-)-lactate is a metabolic product of many bacteria, especially Gram-positive, non-spore-forming anaerobic bacteria (7). It is neither produced nor metabolized by mammals to any great extent (see Discussion) . In man, the episodes seem to be recurrent. Though treatment with oral non-absorbable antibiotics reverses the symptomatology concomitant with a decrease in the concentration of n(-)-lactate in serum, the episodes often subside spontaneously, probably owing to voluntary restriction of oral food intake (1). The assay we describe here allows almost any clinical laboratory to rapidly identify n(-)-lactate as the cause of this encephalopathy, and should avoid long and expensive search for other etiologies of these patients' symptoms. Store frozen at -70 #{176}C, at which temperature it is stable for at least six months.
Materials and Methods

Materials
Controls. Prepare a low serum control from pooled serum and a medium and a high control from pooled serum supplemented with (-)-lactic acid. Store frozen at -70 #{176}C, at which temperature these controls are stable for at least six months.
Procedure
Collect blood in either plain tubes or lithium heparincontaining tubes and separate the serum or plasma the same day. Set the rotor loader to deliver 60 ILL of NAD reagent and 15 ILL of working n( -)-lactate standard (cuvette no. 1) or patients' serum or plasma (cuvettes no. 2-20) together with 15 ILL of wash water to each "sample" well, and 60 pL of n( -)-lactate dehydrogenase reagent and 30 /LL of wash water to each "reagent" well. Allow any endogenous dehydrogenases and substrates from either in vivo pathological processes or from in vitro erythrocyte lysis (i.e., L( + )-lactate and L(+)-lactate dehydrogenase) to equilibrate with the NAD by preincubating the loaded rotor at 30#{176}C in the analyzer at the "incubate" speed (100 rpm for the Multistat ifi) for 20 mm for mixing. Initiate the r( -)-lactate dehydrogenase reaction, using the following instrument settings: first filter, no. 1 (340 nm); second filter, no. 1(340 nm); delay to first reading, 30 8; delay from first to second reading, 300 5; number of data points, 2; start mode, 1 (mixes contents of "sample" and "reagent" wells immediately on pressing the "start" button). The contents of the two wells are thus mixed by rapid acceleration and stopping and the D( -)-lactate concentrations calculated by comparing the increase in absorbance during the interval 30s to 330 s after mixing for the 10 mmolJL aqueous standard and the specimens.
Results
The absorbance-concentration relationship is linear to about 12 mmol/L, after which there is a progressively larger underestimate of n(-)-lactateconcentration: 18% low at 20 mmol/L and about 30% low at 30 mmol/L. Sera with values exceeding 12 mmol/L can be diluted with isotonic saline before analysis, the results being accurate for concentrations up to about 25 mmoltL, but this is rarely necessary because the clinically important range lies somewhere between 3 and 12 mmoIJL (see below). Table 1 details betweenday precision. Analytical recovery when 9.2 mmol of n( -)-lactate was added per liter to nine randomly selected sera was 99.5% (SD 3.4%, range 8.7 to 9.5 mmol/L). Grossly lipemic sera showed lower recoveries (50-90%) but proanalysis ultracentrifugation at 140 000 x g resolved this problem. Icteric, hemolyzed, and slightly lipemic sera showed no interferences. Assays run on heparinized plasma and sera yielded essentially identical results. Sera before and after addition of as much as 50 mmol of L( + )-lactate per liter gave the same results for r-lactate concentration. This lack of response to L(+ )-lactate was confirmed for each new lot of n(-)-lactate dehydrogenase. Sera collected from 28 healthy laboratory personnel showed a mean D(-)-lactate concentration of 100 /Lmol/L (SD 30 ILmoI!L, range 30 to 180 tmoIJL). Note that the SD for the n(-)-lactate distribution in normal subjects is approximately the same as the withinday SD for the low serum control pool, suggesting that most of the variation in the "normal" range comes from random analytical error.
Case study: A 47-year-old woman on whom a jejunoileobypass was done in 1976 reported repeated episodes over the last several years of disorientation, ataxia, and dysarthria, lasting for one to two days. To investigate the feasibility of using salivary urea nitrogen as an index of renal glomerular filtration rate, we developed and applied a new analytical system consisting of a ureasecontaining test strip and an automatic reflectance spectrometer. The concentrations of urea nitrogen so determined correlate well (r = 0.93) with concentrations in serum. These preliminary data suggest that our method can be used routinely as a simple and reliable means of detecting abnormalities of renal function.
Additional Keyphrases: urea nitrogen . glomerular filtrationrate kidney disease Measurement of urea nitrogen in blood is valuable for diagnosing renal diseases, particularly those associated with a reduction in glomerular filtration rate (GFR). However, specimens are obtained by venipuncture, an invasive technique. We have developed an alternative, noninvasive technique, a dry-reagent test strip. Use of the strip is based on the observation (1) that the concentration of urea nitrogen in saliva reflects its concentration in serum so that one may validly substitute saliva for serum as the sample.
